Salix Pharmaceuticals Ltd (NASDAQ:SLXP)

Monday’s trading has closed, but SLXP is being traded in the after-hours session. After-Hours quote »
172.65
Delayed Data
As of 3:59pm ET
 +0.05 / +0.03%
Today’s Change
86.00
Today|||52-Week Range
172.98
+50.21%
Year-to-Date
Ohr Pharmaceutical Crashes on Disappointing Eye Drug Data - Analyst Blog
4:34pm / Zacks.com
Obama crackdown fails to stop foreign mergers
Mar 17 / CNNMoney.com
Mallinckrodt Reports Acthar Gel Data on Nephrotic Syndrome - Analyst Blog
4:17pm / Zacks.com
Ruthigen-Pulmatrix Merge, Focus on Respiratory Drugs - Analyst Blog
Mar 17 / Zacks.com
Healthcare sector leads feverish M&A activity
1:01pm / FT.com
Valeant (VRX) Raises Salix Offer, Endo Withdraws Proposal - Analyst Blog
Mar 17 / Zacks.com
Why Synergy Pharmaceuticals, Inc. Is Surging Higher Today.
Mar 26 / MotleyFool.com
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
Mar 17 / Zacks.com
Actavis takes 'specialty pharma' route to health
Mar 26 / FT.com
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
Mar 17 / Zacks.com
4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary
Mar 25 / Zacks.com
Valeant/Salix: resistance is futile
Mar 16 / FT.com
Novartis Reports Positive Data on Psoriasis Drug Cosentyx - Analyst Blog
Mar 23 / Zacks.com
Watchman device approval boosts Boston Scientific
Mar 16 / FT.com
AstraZeneca, Daiichi Sankyo to Co-Market Movantik in U.S. - Analyst Blog
Mar 20 / Zacks.com
Raised offer from Valeant knocks Endo out of Salix race
Mar 16 / FT.com
Week in Review, March 21
Mar 20 / FT.com
Valeant aims to sweeten $14.5bn Salix bid
Mar 13 / FT.com
Tetraphase Closes Public Offering, to Raise $173.1M - Analyst Blog
Mar 19 / Zacks.com
Yield-hungry investors clamour for debt
Mar 13 / FT.com
Valeant (VRX) Prices Shares to Finance Salix Acquisition - Analyst Blog
Mar 18 / Zacks.com
Endo looks to crash Valeant-Salix deal
Mar 11 / FT.com
The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Salix Pharm...
Mar 18 / Zacks.com
AbbVie wins three-way fight over Pharmacyclics
Mar 05 / FT.com

To view my watchlist

Not a member yet?

Sign up now for a free account